Physician profile
Suzanne Gregorio
NPI 1487610127
$4,095.82
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,594 · 2022: $1,781 · 2023: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $706 · Education: $14.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $705.53 |
| Education | $14.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,020.09 | 2021-2023 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $475.17 | 2021-2023 | Linzess |
| Janssen Biotech, INC. | $445.35 | 2021-2023 | Stelara, Simponi Aria, Remicade |
| Abbvie INC. | $432.43 | 2021-2023 | |
| Redhill Biopharma INC. | $340.00 | 2021-2023 | Movantik, Aemcolo, Talicia |
| Nestle Healthcare Nutrition INC. | $255.46 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $181.41 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $157.04 | 2022-2023 | Dupixent |
| Ardelyx, INC. | $149.56 | 2022-2023 | Ibsrela |
| Gilead Sciences, INC. | $140.63 | 2021-2023 | |
| Qol Medical, LLC | $124.15 | 2022 | |
| Genzyme Corporation | $122.11 | 2022-2023 | |
| Evoke Pharma, INC. | $121.47 | 2021-2023 | Gimoti |
| Merck Sharp & Dohme LLC | $87.43 | 2021-2022 | |
| Lucid Diagnostics INC. | $30.42 | 2021-2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $13.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Gregorio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.